Agilent Technologies, Inc. and Exact Sciences Corp., a prominent provider of cancer screening and diagnostic tests, have announced a definitive agreement for the sale of Resolution Bioscience to Exact Sciences. The financial details of the agreement have not been disclosed. Sam Raha, senior vice president at Agilent, expressed satisfaction with the acquisition, noting that Exact Sciences’ significant capabilities in advanced cancer diagnostic testing make Resolution Bioscience a strategic fit. Brian Baranick, general manager of Precision Oncology at Exact Sciences, emphasized the value of integrating Resolution Bioscience’s diagnostics into their portfolio. Resolution Bioscience, which specializes in next-generation sequencing-based precision oncology solutions, was acquired by Agilent in 2021.
- Strategic Acquisition: The acquisition of Resolution Bioscience by Exact Sciences is seen as a strategic move, given Exact’s expertise in advanced cancer diagnostic testing.
- Resolution Bioscience’s Role: Resolution Bioscience is known for its development and commercialization of next-generation sequencing-based precision oncology solutions.
- Growing Demand in Precision Oncology: The acquisition underscores the increasing importance of precision oncology in cancer care, with Exact Sciences aiming to provide actionable genomic insights to inform prognosis and treatment post-diagnosis.